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Abstract 
Background/Aims 
Nonalcoholic steatohepatitis (NASH) is prevalent in both economically developed and 
developing countries. Twenty percent of patients with NASH progress to cirrhosis 
with/without hepatocellular carcinoma, and there is an urgent need to identify biomarkers to 
facilitate early diagnosis and monitor disease progression. Approximately 30% of patients 
with NASH have diabetes mellitus or insulin resistance. According to the nonalcoholic fatty 
liver disease and NASH guidelines published by the Japan Society of Hepatology, 
pioglitazone is used for treatment in patients with concomitant diabetes mellitus or insulin 
resistance. Liver fibrosis is denoted by an increase in collagen production around hepatic 
parenchymal cells and stromal cells by activated hepatic stellate cells due to steatosis. In 
addition, various cytokines, matrix metalloproteinases (MMPs), and tissue inhibitors of 
metalloproteinases (TIMPs) promote fibrosis. The present study investigated whether serum 
cytokine, MMP, and TIMP levels reflect disease activity to permit early detection and 
treatment in patients with NASH. 
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Methods 
This study was conducted at the Kitasato University Medical Center and International 
University of Health and Welfare Hospital between April 1, 2013 and December 31, 2016. 
Prior to implementation, the study protocol was approved by the ethics committee of both 
institutions. All patients provided written informed consent. Thirty-three patients with 
histologically proven NASH (24 men and 9 women; mean age, 50.6 ± 12.3 years) were enrolled 
in addition to 14 health controls (9 men and 5 women; mean age, 51.9 ± 13.2 years). Serum 
levels of MMP-1, MMP-2, MMP-9, TIMP-1, TIMP-2, stromal cell-derived factor 1α, stem 
cell factor-1, stem cell growth factor-β, monocyte chemotactic protein-1 (MCP-1), 
granulocyte-colony stimulating factor, leptin, and ghrelin were measured via a fluorescent 
beads-based immunoassay. Next, changes in their levels in response to lifestyle 
modification (diet/exercise) and pioglitazone treatment were examined. 
 
Results 
Serum leptin and MCP-1 levels were significantly increased in the fibrosis stage 1 (F1) 
group than healthy controls and the F2 group. In addition, serum MMP-1 levels were 
significantly higher in the F1 group than in healthy controls, although this finding did not 
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hold for more advanced fibrosis stages. TIMP-1 and TIMP-2 levels were not elevated in the 
F1 group. Serum MMP-1 levels in patients with NASH reflected disease activity estimated 
using serum aminotransferase values during the follow-up period. Conversely, MMP-2, 
MMP-9, and TIMP levels did not change with changes in disease activity. In a comparison 
between the F1 and F2 groups, pioglitazone treatment tended to decrease MMP-1 levels in 
the F1 group after 2 months. 
 
Discussion 
Serum levels of cytokines related to macrophage and hepatic stellate cell activation were 
not elevated in the F1 group. In addition, as TIMP levels increased in the same stage, it was 
considered that MMP-1 serum concentrations had increased. Histologically, MMP-1 
expression has been reported to be increased in monocytes, Kupffer cells, and hepatic stellate 
cells in early-stage NASH. Relationships between hepatic stem and progenitor cells have also 
been suggested for histological MMP-1 level elevation. The decrease of MMP-1 levels was 
considered the result of reduced collagen production following improvement of ALT levels, 
inflammation, and steatosis due to lifestyle modification and pioglitazone treatment. These 
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results suggest that serum MMP-1 levels reflect disease activity and that they may serve as a 
potential biomarker for monitoring the progression of NASH. 
 
Conclusions 
MMP-1 was considered a biomarker for the early detection and treatment evaluation of 
NASH in the early stage, in which serum leptin and MCP-1 levels are increasing. 
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Introduction 
Nonalcoholic steatohepatitis (NASH) is prevalent in both economically developed and 
developing countries. (1) In Japan, the number of patients with NASH has been increasing in 
recent years. (2) Most patients with NASH exhibit increased body weight due to overeating 
and low physical activity, and they frequently present with metabolic syndrome and diabetes 
mellitus. (3, 4) Triglyceride (TG) deposits in hepatocytes cause oxidative stress in 
mitochondria, leading to the death of hepatocytes and inflammation with infiltration of 
monocytes (MCs) into the liver (3-6) as well as hepatocellular carcinoma (HCC) with or 
without cirrhosis. (7) If inflammation is not observed, then the term nonalcoholic fatty liver 
(NAFL) is generally used in clinical practice, and the term nonalcoholic fatty liver disease 
(NAFLD) includes both NASH and NAFL. (4) According to the NAFLD and NASH guidelines 
published by the Japan Society of Hepatology, pioglitazone is used for treatment when patients 
have concomitant diabetes mellitus or insulin resistance. (8) 
There are two clinical problems associated with NASH. One is that liver biopsy is 
necessary to diagnose simple fatty liver and NASH. The invasiveness of liver biopsy results in 
bleeding, in addition to the time and cost required for examination. Therefore, liver biopsy is 
not performed in all patients with suspected NASH. The other issue is that NASH progresses 
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without subjective symptoms. In general, the subjective symptoms of liver diseases such as 
liver cirrhosis include fatigue, jaundice, and ascites, but these are difficult to detect in earlier 
stages because of the compensatory mechanisms of the liver. In addition, if a person with 
abnormal liver function data in an annual medical examination does not receive further scrutiny, 
the diagnosis of NASH will be delayed. 
NASH increases the risk of liver cancer. Globally, the carcinogenesis rate of NALFD is 
assumed to be approximately 0.5% (9), versus 2–5% for NASH. (10, 11) In addition, as patients 
with NASH develop cirrhosis over a period of 10–15 years, early detection and treatment 
before cirrhosis and liver cancer appear are important. 
Various cytokines are involved in the development of NASH. Cytokines secreted from 
adipocytes are called adipocytokines. Leptin, which has an appetite-lowering effect, is an 
adipocytokine, and leptin resistance leads to high levels of this adipocytokine in patients with 
NAFLD. Leptin resistance enhances overeating and obesity. (12) Ghrelin is an adipocytokine 
that promotes appetite, and its blood concentration is decreased in obese patients. (12) In 
patients with inflammation due to adipocytes and fatty liver, the concentration of MC 
chemotactic factor 1 (MCP-1) is increased. MCP-1 promotes hepatitis and hepatic fibrosis by 
activating macrophages. (13) Conversely, in the presence of cytotoxicity due to inflammation, 
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hepatic parenchymal and stromal cells are regenerated without mitosis via stem or progenitor 
cell recruitment. (14) Stem cell factor 1 (SCF-1), stem cell growth factor β (SCGF-β), and 
stromal cell-derived factor-1α (SDF-1α) have been reported as factors for liver regeneration. 
(15-17) SDF-1α activates hepatic stellate cells (HSCs) and promotes hepatic fibrosis. (18) 
Matrix metalloproteinase (MMPs), which are extracellular matrix (ECM)-degrading enzymes, 
facilitate the improvement of hepatic fibrosis. (4) MMP-1, MMP-2, and MMP-9 are involved 
in the degradation of collagen, which causes fibrosis in the liver. TIMPs inhibit MMP activation. 
Various cytokines, MMPs, and TIMPs have been inferred to play important roles in fibrosis 
formation in early NASH. 
Therefore, in this study, we aimed to clarify whether NASH can be detected early or 
whether therapeutic effects can be assessed by measuring the blood concentrations of 
biomarkers involved in NASH. 
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Chapter 1 
This chapter discusses the histological structure of the liver and the mechanism of liver 
fibrosis. In addition, this chapter explains the pathology and treatment of NAFLD and NASH 
in detail. 
 
Overview of liver structure 
The liver is generally composed of two cell populations, namely the parenchyma and 
mesenchyme. The parenchyma is a tissue that performs liver functions such as metabolism and 
detoxification, and it is composed of hepatocytes. Contrarily, mesenchyme tissue supports the 
structures and functions of parenchyma tissue, and it is composed of nonparenchymal cells 
(HSCs, sinusoidal endothelial cells, Kupffer cells [KCs], and cholangiocytes) (Fig. 1). (19) The 
liver is composed of a large number of structures called “hepatic lobules.” A hepatic lobule, 
which has a hexagonal shape, is the smallest structural unit of the liver. Two blood vessels, 
namely the hepatic artery and portal vein, are wrapped within a membrane of connective tissue 
in the bile duct. In particular, the border of the leaflets is called Glisson’s sheath. (19) 
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Fig. 1 Cell structure of the liver 
 
HSCs 
HSCs have an important role in relation to hepatic tissue injury-induced fibrosis. As one of 
the processes to repair disordered tissues, HSCs produce and secrete an ECM including 
collagen. (19, 20) When the liver is injured by inflammation via viral infection or drug allergy, 
various cytokines such as interleukin-1 (IL-1), transforming growth factor-β (TGF-β), and 
platelet-derived growth factor (PDGF) are produced. (4) These cytokines stimulate quiescent 
HSCs, which become activated HSCs (aHSCs), also termed myofibroblast-like cells. aHSCs 
strongly contribute to fibrosis. (21) 
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ECM 
ECM plays an important role in regulating function in cell and tissue networks via cell-cell 
interaction signals using cytokines. (22) ECM regulates a variety of cellular functions such as 
adhesion, migration, differentiation, proliferation, and survival, in addition to supporting 
physical scaffolds and structures for cells. The cellular response is dependent on the 
constitution of ECM; therefore, dysregulation of ECM production and degradation is often 
associated with the development of liver lesions. (23) ECM in normal liver primarily consists 
of collagen, fibronectin, laminin, proteoglycan, and matrix cell proteins. (24) These are mainly 
detected in endothelial cells of Glisson’s sheath, the portal vein area, the central vein, and the 
space of Disse. (25) 
 
Collagen 
Collagen is a polymeric peptide molecule composed of 18 types belonging to the collagen 
family and 30 or more types of polypeptide chains. Collagen is secreted as pro-collagen from 
collagen-producing cells to the extracellular space. Cleavage of three peptides from the C- and 
N-termini by extracellular peptidase converts pro-collagen into collagen. These collagen 
molecules associate via crosslinking at cysteine residues. (26) 
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It is known that types I, III, IV, V, and VI collagen exist in the liver. (27) Type I collagen is 
mainly located in Glisson’s sheath in the liver. Type III collagen is distributed around the 
vasculature and sinusoids. Type IV collagen binds to laminin to form the basement membrane, 
which is distributed in the sinusoid, perivascular, and pericapillary bile ducts and around nerve 
fibers in the liver. (28) Type V collagen is interposed between type III or I collagen on the cell 
surface, basement membrane, or fibrotic areas, and it is responsible for maintaining the tissue 
structure. Type VI collagen is linked to fibrous connective tissue. 
Collagen is degraded via two pathways: extracellular and intracellular. (26, 28) In the 
extracellular pathway, depolymerase removes matrix components such as proteoglycan from 
collagen. Subsequently, the collagen residue is decomposed into TCA (three-quarter length) 
and TCB (one-quarter length) by collagenase, thus becoming gelatin. Gelatin is degraded to 
peptides by gelatinase. Meanwhile, in the intracellular pathway, collagenolytic cathepsin (a 
member of the protease family) is secreted around the cell, and collagen degradation occurs in 
an acidic environment. The decomposed peptides are taken into the cell by the phagocytic 
action of macrophages. 
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Fibrosis 
Overview of fibrosis 
Liver fibrosis occurs as part of the tissue repair mechanism in the liver. Regardless of the 
causative disease, its mechanism plays a central role in ECM overproduction via the activation 
of HSCs. (29) Conversely, excessive ECM production and deposition by activated HSCs 
exacerbate the liver function by decreasing hepatic blood and bile flow. This phenomenon 
causes necrosis of the hepatic parenchyma (hepatocytes), the production of regenerative 
nodules, sinusoidal capillarization, and the progression of fibrous septa due to chronic 
inflammation. Finally, liver cirrhosis arises because of hepatic lobular structure remodeling and 
hemodynamic abnormality. (30) 
 
Mechanism of liver fibrosis 
The mechanism of hepatic fibrosis is currently being elucidated, and HSCs and KCs play 
a central role. When hepatocyte inflammation is prolonged, the ECM environment changes, 
and KCs are activated. Activated KCs produce MMPs, TIMPs, PDGF, and TGF-β. Then, HSCs 
activated by PDGF and TGF-β release collagen, TIMPs, and retinoids. (31) TGF-β and PDGF 
promote fibrotic proliferation and ECM accumulation. (32) In other words, in the liver, KCs 
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and HSCs are deeply involved in the production of substances that promote hepatic fibrosis. 
Additionally, levels of the proteoglycan hyaluronic acid increase over the course of tissue 
inflammation, leading to healing tissue production. TGF-β is involved in the increased 
production of hyaluronic acid. (33) 
As ECM, the production of which is increased by liver fibrosis, accounts for 85% of types 
I and III collagen and it is a structurally stable molecule, collagenases are important for 
improving fibrosis. (28) In addition, gelatinases, which mainly degrade basement membrane 
types IV and V collagen and gelatin, are also important in relation to liver fibrosis. In liver 
fibrosis, the appearance of basement membrane-like structures is observed in contact with 
sinusoidal endothelial cells and hepatocytes. This is called the capillary formation of sinusoid, 
and it causes further hepatocellular injury by decreasing blood flow and substance exchange 
between hepatocytes. The basement membranes are mainly composed of type IV collagen. (26) 
Active oxygen/nitrogen species and pro-inflammatory mediators are released in response 
to direct damage to hepatocytes and organelles, and these species activate innate immune cells. 
(34) Next, activated KCs and infiltrating leukocytes exacerbate the early stage of liver injury. 
(35) In the damaged acute stage liver, ECM proteins such as fibronectin and tenascin are 
synthesized. (36-38) ECM accumulation, which is increased by chronic inflammation, 
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gradually results in the replacement of hepatic parenchyma with scar fibrous tissue. (39) In 
chronic liver injury, hepatic fibrosis occurs due to prolonged activation cycles of HSCs. Liver 
fibrosis causes widespread disability formation, disturbances of liver structure, and disruption 
of liver function. To ameliorate fibrosis, in addition to the removal of myofibroblast-like cells 
that generate scarring, ECM degradation is a necessary. (40) 
 
NAFLD and NASH 
NAFLD is defined as a fatty liver similar to alcoholic liver disease in people who are not 
heavy alcohol drinkers (less than 20 g/day). (41) Many cases of NAFLD are simple steatosis 
(NAFL), and its symptoms are mostly mild. However, 20% of cases of NAFLD are NASH. 
(19, 41) As a historical background of fatty liver disease, Ludwig et al. (42) in 1980 reported a 
case of hepatitis that was histologically similar to alcoholic liver disease that progressed to 
liver cirrhosis despite the absence of alcohol consumption (less than once a week), and this 
case was defined as NASH. In addition, in 1986, Schaffner et al. reported a group of diseases 
with similar pathological findings as alcoholic liver disorder despite the absence of heavy 
alcohol drinking (20 g/day or less) that were defined as NAFLD. (43)  
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Origin of fatty liver disease 
The main etiologies of fatty liver are obesity and insulin resistance. Both etiologies are 
linked to the abnormal secretion of adipocytokines and free fatty acids. Therefore, metabolic 
syndrome and related diseases such as type 2 diabetes, dyslipidemia, and hypertension as 
background diseases are related to insulin resistance, and the relevance between background 
disease and insulin resistance is strongly is strongly considered. (44) Therefore, the increased 
fatty liver is often regarded as a metabolic syndrome phenotype in the liver. NAFL is caused 
by TG accumulation. The balance of two factors, namely increasing (inflow of TGs into the 
hepatocytes and synthesis in hepatocytes) and decreasing factors (consumption and release in 
hepatocytes), is important. Meanwhile, a critical factor for defining NAFL or NASH has not 
been elucidated. In the past, the two-hit theory leading to NASH via NAFL due to secondary 
stress next to fatty deposition in hepatocytes was widely endorsed. Recently, a multifactor hit 
theory that comprises multiple factors such as liver inflammation, oxidative stress, genetic 
factors, and environmental factors was proposed. (45) 
 
Epidemiology of NAFLD 
As the obese population in Japan is growing, the number of patients with metabolic 
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syndrome and NAFLD is increasing steadily. (46) Currently, 20–30% of adults have NAFLD. 
(46) In total, 70–80% of such people are men, although the frequency of NAFLD in women 
has increased over the last 50 years. There is no gender difference in the frequency of NASH, 
and it is estimated to occur at least 1% of adults. (47) 
 
Prognosis of NAFLD 
NAFLD consists of NAFL and NASH. The prognosis is different depending on each 
disease condition. NAFL is less likely to develop into a disease state. (29) Meanwhile, 10–20% 
of cases of NAFLD are NASH, and 5–20% of these cases progress to cirrhosis. The prognosis 
of NASH is estimated according to the stage of fibrosis.  
 
Diagnosis of NAFLD 
Laboratory examination 
Diagnosing NAFLD and NASH is difficult in the laboratory via blood sampling, and liver 
biopsy tissue is absolutely required for a definitive diagnosis. In NAFLD, aspartate 
transaminase (AST) and alanine transaminase (ALT) values are normal or mildly elevated, and 
findings such as diabetes and dyslipidemia based on insulin resistance are commonly found. 
  19 
(48) 
NAFL and NASH differ from alcoholic steatohepatitis (ASH) according to laboratory data. 
The ALT/AST ratio is high in patients with NAFL and NASH and low in patients with ASH. 
ALT levels are generally less than 200 IU/L in patients with NAFL patients and higher than 
300 IU/L in patients with NASH and severe liver inflammation. (30) The serum levels of 
gamma-glutamyl transpeptidase (γ-GTP) and ALT are slightly elevated in patients with NASH. 
Serum cholesterol and TG levels are high in both patients with NAFL and NASH. Therefore, 
it is difficult to discriminate between NAFL and NASH using only these laboratory data. (30) 
Liver fibrosis is extremely important in the progression of NASH, and some liver fibrosis 
markers are useful in clinical practice. Fibrosis markers such as hyaluronic acid and type IV 
collagen are elevated in patients with NASH plus fibrosis and liver cirrhosis. (49) The number 
of platelets decreases, and this decline is often used to predict the reserve of liver function. 
Recently, Wisteria floribunda agglutinin-positive Mac-2 binding protein is a novel fibrosis 
marker of hepatitis C and B and NAFLD, and high sensitivity, specificity, and diagnostic 
performance have been demonstrated. (50, 51) 
 
Pathological findings by liver biopsy 
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Liver biopsy and laparoscopy are useful for diagnosing liver cirrhosis, but due to sampling 
errors (52) and bias by the evaluator, the accuracy is approximately 80%. (52, 53) Liver biopsy 
for diagnosis is based on the patient’s condition, and it depends on physical findings, laboratory 
data, organization function, and imaging findings. If the patient is elderly and/or has advanced-
stage cirrhosis, liver biopsy should be avoided because of the risk of severe bleeding and 
complications. 
Three indicators are often used for findings of pathological diagnosis. One is the 
classification of Matteoni. (54) NAFLD is consisted NAFL or NASH, but Matteoni et al. (54) 
categorized the disease into 14 types based on the pathological findings. Hepatocellular 
ballooning is observed in types 1 (fatty liver only), 2 (inflammatory fatty liver), 3 
(hepatocellular ballooning with inflammation), and 4 (fibrosis and Mallory Denk bodies). 
Types 3 and 4 are defined as NASH. The second is the classification of Brunt. (55) (Table 1) 
This classification evaluates the pathological findings in NASH according to the extent ratio 
of inflammation and fibrosis. The third is the NAFLD activity score (NAS) proposed by 
Kleiner et al. (56) (Table 2) It scores the degree of steatosis, hepatocyte ballooning, 
inflammation, and NASH. In clinical practice in Japan, pathologists use these classifications 
in combination. 
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Table 1 Staging for Fibrosis by classification of Brunt  
 
Table 2 NASH activity score 
Item Score Extent 
Steatosis 
0 <5% 
1 5-33% 
2 >33-66% 
3 >66% 
Lobular Inflammation 
0 No foci 
1 <2 foci/200x 
2 2-4 foci/200x 
3 >4 foci/200x 
Hepatocyte Ballooning 
0 None 
1 Few balloon cells 
2 Many cells/prominent ballooning 
 
 
Stage Extent 
1 
Zone 3 perisinusoidal/pericellular fibrosis; focally or extensively 
present. 
2 
Zone 3 perisinusoidal/pericellular fibrosis with focal or extensive 
periportal fibrosis. 
3 
Zone 3 perisinusoidal/pericellular fibrosis and portal fibrosis with focal 
or extensive bridging fibrosis. 
4 Cirrhosis. 
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Image findings via abdominal ultrasonography 
Abdominal ultrasonography has high diagnostic ability for fat deposits in hepatocytes. 
Therefore, it is a useful test for diagnosing NAFLD. (57) However, it is difficult to evaluate 
the extent of inflammation and fibrosis, and these findings cannot be used to diagnose early 
NASH. Therefore, Fibroscan®, which is based on transient elastrography (TE), can distinguish 
fibrosis in the liver using ultrasound. It is a method for evaluating the hardness of tissue based 
on differences of the propagation speed of audible vibration generated from its probe .(57, 58) 
Fibroscan was approved for detecting cirrhosis or suspected cases of cirrhosis in October 2011. 
However, TE requires expensive equipment, the recruitment of experienced technicians, and 
extended consulting hours, and patient throughput is low. 
 
Treatment of fatty liver disease 
As it is believed that NASH develops from NAFLD, it is important to not leave fatty liver 
untreated. Therefore, the principle of treatment for NAFLD is treating obesity, diabetes, 
dyslipidemia, and background hypertension via changes in lifestyle such as diet and exercise 
therapy. (29) In addition, oxidative stress and insulin resistance are factors of NASH. In any 
case, there is no established treatment method in Japan at present. To treat NASH, the treatment 
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for original disease is given priority. For example, if a patient has diabetes mellitus, its 
treatment is given priority. 
 
Diet therapy 
Weight loss achieved using a low-calorie diet improves liver function and hepatic steatosis 
in patients with NAFLD. To improve NAFLD, it is necessary to optimize calorie and lipid 
intake. The optimal meal content is 50–60% carbohydrates and 20–25% lipids, but caloric 
restriction is more important than the carbohydrate/lipid ratio for weight loss. 
 
Exercise therapy 
The relationship between exercise and improvements in liver lesions is unclear, but it has 
been reported that exercise therapy improves serum transaminase level and hepatic steatosis in 
patients with NAFLD. (59, 60) 
 
Drug therapy 
Type 2 diabetes treatment 
As insulin resistance is deeply involved in the onset and progression of NASH, the 
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administration of pioglitazone improves liver function and histology in patients with NASH in 
a relatively short period. (12) Pioglitazone histologically improves liver steatosis, mesangial 
inflammation, hepatocyte ballooning, and liver fibrosis. Pioglitazone regulates the 
transcription of insulin sensitivity genes by stimulating peroxisome proliferator-activated 
receptor-γ (PPARγ), it improves insulin sensitivity in muscle and adipose tissue, and it reduces 
insulin resistance in liver and peripheral tissues. (61) On the contrary, the ability of the drug to 
prevent progression to liver cirrhosis and improve prognosis remains unclear. 
 
Drugs for dyslipidemia 
Although HMG-CoA reductase inhibitors can improve serum lipid and ALT levels, there is 
little evidence that they improve liver histology. (62) However, they represent a treatment 
option for patients with NAFLD and hypercholesterolemia. Ezetimibe, a cholesterol 
transporter inhibitor, controls cholesterol absorption from the intestinal tract and generally 
exerts positive effects on lipid levels, including decreases in LDL-cholesterol levels and 
cholesterol transport to the liver. In addition, fatty liver, necrotizing inflammation, and 
hepatocellular balloon-like changes have been reported to be improved by treatment with this 
drug. (63) 
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MMPs, TIMPs, and cytokines 
Cytokines 
Proteinaceous factors released from cells that mediate various cell-cell interactions are 
called cytokines. (64) Specific receptors have been identified for each cytokine. Cytokines play 
important roles in immunity, inflammation, and biological defenses. The common properties 
of cytokines are as follows: (i) protein structure, (ii) exert their effects at extremely low levels, 
(iii) bind to cell surface receptors, (iv) target cell specificity, (v) primarily function at the site 
of production, i.e., act in a paracrine or autocrine manner, and (vi) mutually associated effects, 
i.e., cytokine network. The bioactivity of cytokines includes enhancing and suppressing 
cellular immunity and enhancing antibody production and the proliferation and differentiation 
of hematopoietic cells. Cytokines that regulate white blood cell activity are called chemokines. 
(64) 
 
Leptin 
Leptin is an adipocytokine that acts centrally to exert strong appetite-suppressing effects 
and exhibit various physiological activities such as improving lipid metabolism and increasing 
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blood pressure. (65) Leptin inhibits fat accumulation in non-adipose tissue such as muscle, the 
liver, and the pancreas. Serum leptin levels are elevated in obese patients, reflecting leptin 
resistance. Therefore, the physiological activity of leptin is not sufficient in obese patients. 
Elevated leptin levels have also been demonstrated to accelerate the onset of liver cancer 
through promoting hepatic fibrosis and inducing angiogenesis. (66) In particular, leptin 
suppresses appetite by activating POMC/CART neurons in the arcuate nucleus (ARC) of the 
hypothalamus. Another effect of leptin is suppressing appetite by inhibiting AgRP/RPY 
neurons in the ARC. (67) 
 
Ghrelin 
Ghrelin regulates eating similarly as leptin. It is mainly secreted by the hypothalamic ARC 
in the stomach. In addition to potently inducing hyperphagia, ghrelin has various functions 
such as enhancing gastrointestinal motility, promoting growth hormone secretion, and 
protecting the cardiovascular system. (12) 
 
Chemokine family 
The chemokine family is a generic term for cytokine groups that induce directional cell 
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migration. The action of inducing directional cell migration is called chemotaxis. (64) 
Chemotaxis is performed largely in four steps. (i) Leukocytes are temporarily stopped due to 
gentle binding between selectin and its ligand, rolling on the surface of vascular endothelium 
in posterior capillary venules. Then, chemokine production occurs by various cells due to 
inflammation and homeostasis. (ii) The chemokine present on the vascular endothelial cell 
surface activate leukocytes through its receptor. (iii) Leukocyte integrins are activated, and they 
firmly bind to vascular endothelial cells. (iv) Chemokines migrate to the tissue through blood 
vessels according to the concentration gradient. 
Chemokines have four cysteine residues, which are classified into four subfamilies of CXC, 
CC, (X) C, CX3C (X is another amino acid residue) by two motifs formed on the N-terminal 
side. In these subfamily names, “R” representing the receptor is attached, and likewise, “L” for 
ligand is also attached. CXC and CC chemokines are mainly inflammatory chemokines 
targeting neutrophils, MCs, and eosinophils. In humans, 44 chemokines have been identified. 
In this study, we focused on MCP-1 (also termed CCL 2) and SDF-1 (CXCL 12). 
 
MCP-1 
MCP-1 plays an important role in chronic inflammation and allergic inflammation by 
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modulating the activities of MCs, eosinophils, and memory T cells. MCP-1 is also produced 
by tumor cells, and it participates in macrophage recruitment and stroma formation. CCR2 is 
the receptor of MCP-1. In a CCR2 knockout liver injury mouse model using tetrachloride 
exposure, it was reported that MCP-1 suppresses early fibrosis by reducing the number of 
hepatic infiltrating macrophages. (68) 
 
SDF-1 
Serum SDF-1α serves as a ligand for its receptor CXCR4, and it has been reported to play 
important roles in endothelial progenitor cell mobilization from bone marrow to reach ischemic 
tissue/organs to promote repair/regeneration and angiogenesis. (69) CXCR4 is also expressed 
on sinusoidal endothelial cells and HSCs, and it is believed to contribute to the production and 
proliferation of cells in the liver by controlling trafficking between cells. (18, 70) SDF-1 is 
believed to activate HSCs via sinusoidal endothelial cells expressing CXCR4. (71) Through 
SDF-1/CXCR4 signaling, sinusoidal endothelial cells produce platelet-derived growth factor-
β (PDGF-β). It is considered that PDGF-β activates HSCs and contributes to the promotion of 
fibrosis. In addition, HSCs stimulate hematopoietic stem cell migration to the liver via SDF-
1/CXCR4 signaling. It is considered that hematopoietic stem cells are transformed into hepatic 
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stem/progenitor cells (HPCs), differentiate into bile duct cells, and promote fibrosis in the 
process of forming the bile ducts. (71) SDF-1 is secreted in two forms, namely α and β. 
Between them, SDF-1α is secreted in response to hepatic injury, and it stimulates hepatic 
progenitor cells present around herring canal and bile duct epithelial cells and their controls 
proliferation and differentiation while simultaneously contributing to the induction of fibrosis. 
(72) 
 
Stem cell-related cytokines 
In the mature liver, HPCs are present near the herring canal, which is the point of contact 
between hepatocytes and the interlobular bile duct. (73) When these cells are activated during 
hepatic injury, they are transformed into oval cells, after which they apparently promote liver 
tissue regeneration. It has been hypothesized that HPCs are derived from hematopoietic stem 
cells. In this study, the serum concentrations of cytokines involved in hematopoiesis are 
measured. 
 
SCF-1 
SCF-1 plays an important role in the proliferation and initial differentiation of 
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hematopoietic stem cells. (14) It is secreted as a transmembrane ligand by bone marrow, 
thymus stromal cells, and osteoblasts, forming a hematopoietic microenvironment. The 
receptor, KIT (c-kit gene product), is expressed in hematopoietic stem cells and various 
erythroid, megakaryocytic, myeloid, and lymphoid progenitor cells. 
 
SCGF-β 
SCGF is a hematopoietic growth factor that exerts its activity in the early stages of 
hematopoiesis. SCGF is a non-glycosylated species-specific cytokine capable of supporting 
the proliferation of primitive hematopoietic cells and, in combination with erythropoietin or 
granulocyte colony-stimulating factor (G-CSF), promoting the proliferation of red blood cells 
or bone marrow progenitor cells. (74) It is expressed in skeletal tissues such as bone marrow, 
chondrocytes, perichondrium, and periosteum, and its expression is low in the spleen, thymus, 
and fetal liver. (75) 
 
G-CSF 
G-CSF is also used as a medicine, and its administration promptly increases neutrophil 
counts. (76) G-CSF is produced by fibroblasts, vascular endothelial cells, and other cells 
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stimulated by inflammatory cytokines such as TNF-α and IL-1. (77) Another important 
function of G-CSF is the mobilization of hematopoietic stem cells. G-CSF acts on neutrophils 
and hematopoietic stem cells to induce reconstitution of the hematopoietic stem cell niche 
(microenvironment) in the bone marrow, and indirect actions have been postulated. Meanwhile, 
attention has been paid to its protective action on the central nervous system, cardiac muscle, 
and blood vessels. Hematopoietic stem cells mobilized by G-CSF are believed to promote 
recovery at the lesion site. 
 
ECM-degrading enzyme 
MMPs are enzymes that mainly degrade collagen, and their expression differs in individual 
cells. MMP-1, MMP-2, MMP-3, and MMP-16 are expressed by HSCs. MMP-9 is expressed 
in KCs, and MMP-13 and MMP-14 are expressed by HSCs and KCs. (4) Conversely, TIMPs 
are mainly expressed by HSCs, although TIMP-2 is additionally expressed in KCs. In addition, 
MMP-7 expression has also been reported in hepatocarcinoma cells. As described previously, 
because HSCs express most MMPs and TIMPs together with ECM production, it is considered 
that HSCs have a central role in ECM regulation in the liver. (78) There are many unclear 
points regarding the dynamics of MMPs in vivo. This is due to the multistep involvement of in 
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vivo enzymatic activity, genetic level production, activation of proMMP, and inhibition of 
activity by enzyme inhibitors. (26, 79) 
In the process of improving fibrosis in cirrhotic livers, TIMP, MMP-2, and MMP-9 
expression is slightly decreased, and collagen degradation is also decreased. (80, 81) 
Conversely, MMP-2 is believed to contribute to the improvement of fibrosis as the expression 
of TIMPs is further decreased. (82) Both inactive MMPs and active MMPs are inhibited by 
TIMPs at a 1:1 molar ratio. Therefore, when TIMP levels exceed MMP levels, MMPs do not 
function as decomposing enzymes. (83, 84) In vitro studies illustrated that MMP-2 and TIMP 
levels are elevated in activated HSCs, whereas the release of MMP-1 and MMP-9 is 
decreased.(78) 
 
MMPs 
In general, the collagen content in tissues is defined by the balance between synthesis and 
degradation. If expression is properly maintained, MMPs have important roles in tissue repair 
and wound healing. Meanwhile, when ECM degradation becomes dominant, MMPs cause 
tissue destruction, such as synovial destruction in patients with rheumatoid arthritis. 
Conversely, when the synthetic system becomes excessively activated, tissue fibrosis occurs. 
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This is the main cause of liver fibrosis. MMPs are mainly involved in the degradation of 
collagen in ECM. (85) MMPs are capable of collagen degradation, and they are 
metalloproteases that contain zinc at their active centers. Metalloprotease is a generic term for 
proteolytic enzymes containing metal ions. According to their ECM substrate specificity, 
MMPs are classified into five groups: collagenase, gelatinase, stromelysin, matrilysin, and 
membrane type. (86) 
The primary action of MMPs is the degradation of collagen, proteoglycan, and elastin via 
an extracellular pathway. Regarding MMP gene expression, cytokines such as IL-1 and TNF-
α and cell growth factors are potent inducers that are involved in the pathological destruction 
of connective tissue. MMPs are produced as pro-MMPs and activated via cleavage of the 
propeptides. Meanwhile, their activity is regulated by TIMPs and plasminogen activator 
inhibitor. Regulation of MMPs is roughly divided into two types: regulation at the genetic level 
and regulation of precursor activation. (87) 
Tissue destruction occurs in pathological conditions in which MMP levels exceed TIMP 
levels. Conversely, fibrosis occurs in pathological conditions in which TIMP levels exceed 
MMP levels. It has actually been confirmed that TIMP levels exceed MMP levels in patients 
with liver cirrhosis, pulmonary fibrosis, scleroderma, and arteriosclerosis. Thus, the amount of 
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collagen in tissues is regulated by controlling the expression and activity of MMPs. 
There are several types of MMPs. One classification based on substrates encompasses 
interstitial collagenase, gelatinase, and stromelysin. (88) Interstitial collagenase degrades 
interstitial types I–III collagen. Gelatinase degrades basement membrane collagen type IV 
collagen and the degenerating substance (gelatin) of interstitial collagen. MMP-3 is also 
involved in ECM regulation as a stromelysin that degrades glycoproteins such as proteoglycan 
and fibronectin. In addition to ECM proteolysis, MMPs also regulate inflammation and 
immunity by acting on non-ECM substrates such as cytokines and chemokines. (89) 
 
MMP-1 
MMP-1 degrades fibrillar types I–III collagen. (82) In addition, expression is suppressed 
by TGF-β, as a TGF-β inhibitory element exists in the promoter of MMP-1. (80) Decreases of 
MMP-1 levels and increases of TIMP-1 levels lead to suppression of ECM degradation and 
promote fibrosis. (21) In addition, carbon tetrachloride was administered chronically to rats, 
and experimental liver fibrosis was created to examine the expression of MMP-1. (26) As a 
result, gene expression was strongly observed in the interstitial fibrous septum. In addition, 
expression tended to be relatively high in the early stage of fibrosis and decreased in later stages. 
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Furthermore, MMP-1, MMP-8, and MMP-13 are believed to have roles in anti-fibrosis, owing 
to overexpression, weakened liver fibrosis, and increased hepatocyte proliferation. (79, 90, 91) 
 
MMP-2 
MMP-2 expression markedly increases with the progression of liver fibrosis together with 
that of MMP-14, an upstream activating factor. The substrate of MMP-2 degrades basement 
membrane constituent type IV collagen, but it also degrades type I collagen and partially 
degrades gelatin. Alternatively, inhibition of type I collagen expression by HSCs is mainly 
involved in the remission of hepatic fibrosis. (92-94) Despite the fact that MMP-2 expression 
is enhanced by liver cirrhosis, accumulation of ECM in liver tissue in patients with liver 
cirrhosis is believed to be due to the fact that TIMP expression is enhanced in cirrhosis, leading 
to the complete suppression of MMP-2 activity. (82) Therefore, MMP-2 exerts its action by 
decreasing TIMP expression, potentially contribute to the improvement of liver fibrosis. (37) 
Meanwhile, MMP-2 degrades type IV collagen in the Disse cavity, changing the 
composition of the matrix. This change suggests activation of HSCs or increased matrix 
production in myofibroblast-like cells via integrin, which promotes hepatic fibrosis. (95-97) 
The present findings did not clarify whether MMP-2 improves liver fibrosis or promotes 
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progression. In addition, it is believed that MMP-2 is responsible for maintaining the 
homeostasis of liver vessels by participating in the TGF-β activation pathway. (34) 
Furthermore, in addition to TGF-β activation, activation of IL-1, TNF-α, and MCP-3 can be 
regulated via proteolytic cleavage. (13, 98) 
 
MMP-9 
MMP-9 has been identified from the fraction of CD11BHi F4/80int Ly-6Cl° macrophages 
associated with the remission of fibrosis. (99) MMP-9 expression has been confirmed in the 
early stages of hepatic fibrosis, and it activates TGF-β, a major fibrosis-inducible cytokine 
from the ECM storage site. (40, 100, 101) In addition, in the presence of low TIMP-1 
concentrations , MMP-9 can promote HSC apoptosis. (40) 
 
TIMPs 
TIMPs are endogenous MMP inhibitors that suppress the overexpression of active MMPs. 
(78) TIMP-1 is a glycoprotein with a molecular weight of 29 kDa, and TIMP-2 is a non-glycan 
protein with a molecular weight of 23 kDa. TIMP-1 and TIMP-2 production is similar in cells. 
Cytokines and growth factors are involved in the expression of TIMP and MMP mRNA. TIMPs 
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promote TGF-β and IL-6 production while suppressing corticosteroid production. TIMPs bind 
1:1 with inactive and active MMPs to regulate their activity. Currently, TIMP-1, TIMP-2, 
TIMP-3, and TIMP-4 are known, and TIMP-1 and TIMP-2 are important for inhibiting MMPs. 
Meanwhile, TIMP-1, TIMP-2, and TIMP-3 expression has been reported in the liver. 
TIMP-1 and TIMP-2 are expressed at high levels in a mouse liver fibrosis model following 
carbon tetrachloride administration (102), and TIMP-1 overexpression is due to activation of 
HSCs after carbon tetrachloride administration. Apoptosis and MMP-2 activation in liver tissue 
were suppressed, and the improvement of hepatic fibrosis was significantly inhibited. (37) 
Additionally, upon amelioration of fibrosis, a rapid decline in TIMP levels is observed, and the 
MMP/TIMP balance is restored, resulting in increased matrix degradation activity and a net 
reduction in scar tissue. (103, 104) 
 
TIMP-1 
Activated HSCs exhibit marked upregulation of TIMP-1 prior to collagen expression and 
potently inhibit MMP activity. (104, 105) The important roles of TIMP-1 in fibrosis and 
remission have been confirmed using the genetic recombination system of mice. TIMP-1 
overexpression in the liver is believed to both accelerate fibrosis and interfere with the 
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remission of scar tissue. (106) TIMP-1 also has an anti-apoptotic effect on liver myofibroblast-
like cells. (107) In other words, the loss of TIMP-1 in convalescence indicates that it contributes 
to the reduction of scar-producing cells in the liver. 
 
TIMP-2 
Treatment of hepatic fibrosis model mice using synthetic siRNA targeting TIMP-2 has been 
reported to improve HSC activation and collagen accumulation to reverse fibrosis. (108) 
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Chapter 2 
Background 
NASH increases the risk of liver cirrhosis and liver cancer due to the progression of liver 
inflammation and fibrosis. Therefore, early detection and diagnosis are important. Liver 
fibrosis is reflected by an increase in collagen production around hepatic parenchymal cells 
and stromal cells by activated HSCs due to steatosis. In addition, various cytokines, MMPs, 
and TIMPs promote fibrosis. In this chapter, we focused on serum concentrations of cytokine, 
MMP, and TIMP in patients with NASH and examined the relationship between their serum 
concentrations and the hepatic fibrosis stage. 
 
 
Methods 
Patient entry and study criteria 
This study was conducted at the Kitasato University Medical Center (Kitamoto City, 
Saitama, Japan) and the International University of Health and Welfare Hospital (Nasu-
Shiobara City, Tochigi, Japan) between April 1, 2013 and December 31, 2016. Prior to 
implementation, the study protocol was approved by the ethics committee of both institutions. 
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All patients provided written informed consent for study participation. Thirty-three patients 
with histologically proven NASH (24 men and 9 women; mean age, 50.6 ± 12.3 years) were 
entered (Table 3, Supplementary Table 1). Fourteen healthy persons (9 men and 5 women; 
mean age, 51.9 ± 13.2 years) who visited the Preventive Medical Center of the International 
University of Health and Welfare Hospital (Nasu-Shiobara City, Tochigi, Japan) for annual 
health examinations were additionally enrolled. 
People who underwent the annual health examination completed questionnaires (present 
complaint, past medical history, family medical history, drinking and smoking habits, diet 
health conditions, physical activity, sleeping time, and current drug use), a physical 
examination (including body weight, waist, and BMI), conventional laboratory tests including 
urinalysis, peripheral blood examination, clinical chemistry (blood sugar level, hemoglobin 
A1c [HbA1c], total cholesterol, TG, high-density lipoprotein [HDL]-cholesterol, creatinine, 
AST, ALT, γ-GTP, CRP), stool occult blood examination, chest X-ray, electrocardiogram, 
upper GI endoscopy, and abdominal ultrasonography. In total, 53 people visited our institution 
on July 14–15, 2015, 14 of whom had normal results, including normal ALT levels, the absence 
of fatty liver on ultrasonography, the absence of diabetes, metabolic syndrome, or 
cardiovascular disease, and normal BMI (18.5–25). 
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The exclusion criteria for patients with NASH were as follows: alcohol consumption of 
more than 20 g/day for men and more than 10 g/day for women; use of a hepatotoxic drug 
or any agent that alters cytokine levels, e.g., interferon; and the presence of complications, 
such as alcoholic steatohepatitis, chronic hepatitis B, chronic hepatitis C, primary biliary 
cholangitis, primary sclerosing cholangitis, chronic pancreatitis, type 1 diabetes, 
uncontrolled thyroid deficiency, renal failure, or a need for hemodialysis, as reported 
previously. (109) 
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Table 3. Clinical and laboratory data of healthy controls and patients with early- and advanced-
stage NASH 
 Healthy controls Early NASH Advanced NASH 
Number 14 24 9 
Men/Women 9/5 18/6 6/3 
Age (years) 51.9 ± 13.2 46.1 ± 9.6 64.1 ± 11.5 
BMI (kg/m2) 23.2  ± 2.95 28.5 ± 4.7** 25.7 ± 2.5† 
Diabetes  0  3 (12.5%) 6 (66.7%) 
Metabolic syndrome  0  12 (50.0%) 6 (66.7%) 
AST (IU/l) 21.0  ± 4.3 54.5 ± 29.5** 60.9 ± 24.9** 
ALT (IU/l) 18.7  ± 5.0 89.7 ± 57.2** 71.0 ± 25.4**† 
γ-GTP (IU/l) 23.7  ± 10.2 62.0 ± 52.5** 163.5 ± 50.6**†† 
TC (mg/dl) 208.1  ± 25.6 211.0 ± 43.6 173.3 ± 26.2**†† 
LDL (mg/dl) 135.3  ± 22.3 132.0 ± 32.2 88.8 ± 13.3*† 
HDL (mg/dl) 55.2  ± 16.2 46.4 ± 8.9 53.5 ± 25.4 
TG (mg/dl) 92.9  ± 43.0 208.6 ± 155.2** 135.7 ± 79.3† 
BS (mg/dl) 94.3  ± 8.3 113.4 ± 44.1** 143.8 ± 42.5*† 
HbA1c (%) 5.6  ± 0.4 6.2 ± 1.2** 7.1 ± 1.1*† 
Plt (103/µl) 242.6 ± 65.5 213.9 ± 63.0 141.0 ± 37.7*† 
Histological characteristics       
 Steatosis grade (1/2/3) 4/15/5 4/5/0 
 Ballooning grade (1/2) 9/15 5/4 
 Inflammation grade (1/2/3) 11/11/2 2/5/2 
 Fibrosis stage (1/2/3/4) 14/10/0/0 0/0/3/6 
Values are presented as the mean ± standard deviation or number. Abbreviations: BMI, body mass 
index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, gamma-glutamyl 
transpeptidase; TC, total cholesterol; LDL, low-density lipoprotein cholesterol; HDL, high-density 
lipoprotein cholesterol; TG, triglyceride. Comparisons between patients with NASH and healthy 
controls: * p < 0.05, ** p < 0.01. Comparisons between patients with early- and advanced-stage NASH: 
† p < 0.05, †† p < 0.01. 
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Histological examination of liver biopsy specimens, fibrosis, and NAS 
Tissue samples were obtained via liver biopsy and fixed for optical microscopy as 
described previously (109). Conventional histological examination was performed using 
hematoxylin and eosin, Azan-Mallory, and silver staining. Histological evaluation was 
performed using optical microscopy and described according to Brunt’s classification. (55) 
Steatosis and inflammation were graded on a scale of 0–3 (0, none; 1, mild; 2, moderate; 
3, severe), and ballooning was graded on a scale of 0–2 (0, none; 1, mild; 2, moderate). 
Fibrosis was graded on a scale of 0–4 (0, no fibrosis; 1, pericellular or isolated portal 
fibrosis; 2, combined pericellular and portal fibrosis; 3, bridging fibrosis; and 4, cirrhosis) 
according to the classification of Brunt. These scales were evaluated according to the NAS. 
(110) 
 
Patients with NASH were categorized into two groups according to Brunt’s staging. 
(55) Stages 1 and 2 comprised early-stage NASH (n = 24) whereas stages 3 and 4 denoted 
advanced-stage NASH (n = 9). The early-stage group included 18 men and 6 women, 
whereas the advanced-stage group included six men and three women. Patients in the early-
stage group were younger than those with advanced-stage NASH (46.1 ± 9.6 years vs. 64.1 
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± 11.5 years), although the difference was not significant (Table 3). 
The mean BMI, AST, ALT, γ-GTP, TG, BS, and HbA1c values in the early- and 
advanced-stage NASH groups were significantly different from those for healthy controls. 
The mean ALT, γ-GTP, TC, LDL, TG, BS, HbA1c, and platelet values were significantly 
different between the early- and advanced-stage NASH groups (Table 3). The 
pharmacological effects of pioglitazone, bezafibrate, ezetimibe, and other medications 
were investigated in patients with NASH. 
 
Assay methods for serum MMP/TIMP and cytokine levels 
Serum MMP-1, MMP-2, MMP-9, TIMP-1, TIMP-2, SDF-1α, SCF-1, SCGF-β, MCP-1, 
G-CSF, leptin, and ghrelin levels were measured using a fluorescent beads-based 
immunoassay (Bio-Plex® 200, Bio-Rad Laboratories Inc., Hercules, CA, USA), and kits 
including antibodies, detection antibodies, and standard controls were used. The samples 
and standard blanks were diluted 1:4 with sample buffer in a 96-well plate, to which the 
bead-based capture antibody was added, followed by incubation on a shaker for 60 min at 
room temperature protected from light and three washes with buffer. The detection antibody 
was added to each well, followed by incubation on a shaker for 30 min at room temperature 
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with protection from light. After incubation and three washes with wash buffer, streptavidin 
was added to each well, followed by incubation for 10 min and three washes with wash 
buffer. Samples were resuspended with beads in assay buffer. Then, the measured optical 
densities against beads with the bead system and blank values were subtracted from all 
readings. Serum MMPs, TIMPs, and cytokine levels were determined using the optical 
densities. The means of duplicate values were used as the measurement data. 
 
Evaluation of disease activity relative to serum MMP/TIMP and cytokine levels 
ALT levels in patients with NASH were used to monitor disease activity. (111) Serum 
MMP/TIMP and cytokine levels were measured several times throughout the clinical course in 
15 of 33 patients with NASH. The 15 patients were divided into two groups (ALT improved 
and uncontrolled) and analyzed at 0, 21, 35, and 70 weeks. All eight patients in the ALT 
improved group exhibited ALT levels < 30 IU/l in the final observation at 70 weeks, and all 
seven patients in the ALT uncontrolled group displayed ALT levels ≥ 30 IU/l at 70 weeks. The 
ALT levels in the two groups were compared with serum MMP, TIMP, and cytokine levels at 
the same time points. 
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Pharmacological effects of pioglitazone on disease activity in patients with NASH 
After serum HDL, TG, LDL, and HbA1c levels were stabilized following the 
administration of lipid-lowering or anti-diabetic agents, we evaluated the effect of 
pioglitazone on disease activity. Seventeen patients with NASH were treated with 15 mg 
of pioglitazone once daily for 2 months, and serum MMP, TIMP, and cytokine levels were 
measured before and after treatment. Clinical manifestations, physical findings, and clinical 
hematological and biochemical data were additionally compared between before and after 
the treatment. 
 
Effects of extrahepatic inflammatory conditions on serum MMP-1 levels 
Patients with diabetes and/or metabolic syndrome were analyzed to ascertain the 
relationship between serum MMP-1 levels and HbA1c levels as well as certain clinical findings 
of metabolic syndrome as markers of the extrahepatic inflammatory conditions observed in 
patients with NASH. 
 
Statistical analysis 
All statistical analyses were performed using EZR version 1.32 (Saitama Medical Center, 
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Jichi Medical University), which is a graphic user interface for R (The R Foundation for 
Statistical Computing, version 2.2.0). (112) 
Biomarker levels were expressed as the mean ± standard deviation. Clinical data were 
adjusted post hoc using the Mann Whitney U test for multiple comparisons with 
Bonferroni’s correction after Kruskal–Wallis analysis of variance. Comparisons between 
controls and grades of cytokines were performed using Steel’s test. Spearman’s rank 
correlation was used for correlation analysis of data. A p value of less than 0.05 was 
regarded as statistically significant for all analyses. 
 
Results 
Serum MMP/TIMP levels in patients with early- and advanced-stage NASH  
Serum MMP and TIMP levels in patients with early- (n = 24) and advanced-stage NASH 
(n = 9) were compared with those in healthy controls (n = 14). Serum MMP-1 and MMP-9 
levels tended to be higher in patients with early-stage NASH than in those with advanced-stage 
NASH or healthy controls, albeit without statistical significance (Fig. 2). Serum MMP-2, 
TIMP-1, and TIMP-2 levels were significantly higher in patients with advanced-stage NASH 
than in those with early-stage NASH and controls (Fig. 2). 
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Fig. 2. Comparison of serum MMP, TIMP, and cytokine levels between patients with early- or 
advanced-stage NASH and healthy controls. 
Serum MMP-1 and MMP-9 levels in patients with early-stage NASH tended to be higher than 
those in patients with advanced-stage NASH and healthy controls without statistical 
significance. Serum MMP-2 and TIMP-1 levels were significantly higher in patients with 
advanced-stage NASH than in healthy controls. Serum cytokine levels were significantly 
higher in patients with NASH. * p < 0.05, ** p < 0.01.  
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Relationship between serum MMP/TIMP levels and histological findings in patients with 
NASH 
Serum MMP and TIMP levels in patients were compared with those in healthy controls 
based on histological characteristics, i.e., steatosis, inflammation, ballooning, and fibrosis. 
 
Serum MMP-1 levels: As shown in Fig. 3, serum MMP-1 levels were significantly higher in 
patients with stage 1 fibrosis (F1 group) than in healthy controls (p = 0.019), but no 
correlation was observed between MMP-1 levels and fibrosis stage (Table 4). Similarly, 
serum MMP-1 levels were higher in patients with grade 2 steatosis and grades 1–2 
inflammation than in healthy controls, but no correlation between serum MMP-1 levels and 
histological grades was noted (Table 5). 
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Fig. 3. Serum MMP, TIMP, and cytokine levels in patients with NASH and healthy controls by 
fibrosis stage. 
The numbers of patients were as follows: F1 NASH group (n = 14), F2 NASH group (n = 10), 
F3+F4 NASH group (n = 9), and healthy controls (n = 14). Compared to healthy controls, 
significant increases were observed for serum MMP-1 levels in the F1 group (p < 0.01), serum 
MMP-2 levels in the F4 group (p < 0.01), and serum TIMP-1 levels in the F4 group (p < 0.01). 
Serum SDF-1α levels were significantly higher in the F2, F3, and F4 groups than in healthy 
controls. Serum G-CSF levels were significantly higher in the F3 group than in healthy controls. 
Serum MCP-1 and leptin levels were significantly higher in the F1 group than in healthy 
controls. * p < 0.05, ** p < 0.01. 
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Table 4. Correlations of serum MMP, TIMP, and cytokine levels with histological 
characteristics 
	  Steatosis Inflammation Ballooning Fibrosis 
 
Correlation 
coefficient 
p 
Correlation 
coefficient 
p 
Correlation 
coefficient 
p 
Correlation 
coefficient 
p 
(r) value (r) value (r) value (r) value 
MMP-1 0.075 0.635 0.068 0.663 0.215 0.167 −0.131 0.402 
MMP-2 0.064 0.669 0.188 0.206 0.096 0.522 0.286 0.051 
MMP-9 0.182 0.22 0.085 0.572 0.188 0.206 −0.116 0.436 
TIMP-1 0.227 0.125 0.256 0.082 0.359 0.013 0.304 0.038 
TIMP-2 0.069 0.644 0.19 0.201 0.315 0.031 0.275 0.062 
SDF-1α 0.415 0.005 0.522 <0.001 0.433 0.002 0.649 <0.001 
SCF -1 0.047 0.775 0.151 0.358 0.049 0.769 0.233 0.153 
SCGF-β 0.36 0.025 0.4 0.012 0.416 0.008 0.295 0.069 
MCP-1 0.472 0.002 0.443 0.005 0.529 0.001 0.321 0.046 
G-CSF 0.048 0.861 0.2 0.458 0.139 0.607 0.03 0.912 
Leptin 0.505 0.001 0.483 0.002 0.453 0.004 0.334 0.038 
Ghrelin −0.151 0.371 −0.077 0.649 −0.178 0.293 −0.169 0.317 
Values significant at p < 0.05 are printed in bold type. 
 
Serum MMP-2 levels: Serum MMP-2 levels in the F4 group were significantly higher than 
those in healthy controls (p < 0.01, Fig. 3). Serum MMP-2 levels tended to be higher in the 
grade 1 steatosis, grade 3 inflammation, grade 2 ballooning, and F3 groups than in healthy 
controls (Table 5). The correlation between serum MMP-2 levels and fibrosis stage approached 
significance (p = 0.051) (Table 4). 
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Table 5. Serum MMP and TIMP levels in patients with NASH and healthy controls by 
histological grade 
 
 
MMP-1 
(ng/ml) 
MMP-2 
(ng/ml) 
MMP-9 
(ng/ml) 
TIMP-1 
(ng/ml) 
TIMP-2 
(ng/ml) 
Healthy controls 1.28 ± 1.08 33.2 ± 13.6 28.0 ± 24.6 119.5 ± 24.7 57.1 ± 40.5 
Steatosis 
1 1.27 ± 0.83 42.2 ± 15.8 22.8 ± 20.2 123.4 ± 22.7 58.6 ± 15.0 
2 1.71 ± 1.93 37.5 ± 18.3 32.0 ± 27.6 135.9 ± 34.3 57.0 ± 15.9 
3 1.24 ± 1.14 37.2 ± 15.9 27.7 ± 9.0 133.1 ± 32.5 57.7 ± 13.7 
Inflammation 
1 1.52 ± 1.77 39.5 ± 18.3 35.1 ± 33.9 122.0 ± 21.0 56.3 ± 13.8 
2 1.67 ± 1.68 35.8 ± 13.6 23.1 ± 13.6 131.7 ± 22.8 54.4 ± 9.7 
3 0.96 ± 0.44 46.5 ± 26.1 33.7 ± 11.8 169.6 ± 60.8 73.5 ± 27.2 
Ballooning 
1 1.18 ± 1.53 40.2 ± 16.5 16.5 ± 18.5 116.5 ± 16.3 51.0 ± 11.2 
2 1.39 ± 0.92 43.0 ± 21.7 21.7 ± 15.0 141.2 ± 42.5 63.2 ± 19.5 
Fibrosis 
1 2.09 ± 0.66* 36.7 ± 15.5 38.6 ± 29.1 124.7 ± 16.8 53.4 ± 9.8 
2 0.85 ± 0.48 29.1 ± 4.8 26.8 ± 21.1 126.9 ± 32.8 55.3 ± 11.3 
3 0.64 ± 0.20 43.2 ± 6.8 14.6 ± 3.7 120.8 ± 14.2 50.5 ± 13.3 
4 0.80 ± 0.40 56.5 ± 23.9** 18.0 ± 8.4 165.6 ± 42.8** 74.1 ± 21.3 
Values are presented as the mean ± standard deviation. Comparisons between patients with NASH and 
healthy controls: * p < 0.05, ** p < 0.01. 	
 
 
Serum MMP-9 levels: Similar to the findings for MMP-1 levels, serum MMP-9 levels tended 
to be higher in the grade 2 steatosis, grade 2 inflammation, and F1 groups than in healthy 
controls, as shown in Table 5 and Fig. 3. There was no correlation between serum MMP-9 
levels and histological grades (Table 4). 
 
Serum TIMP levels: Serum TIMP-1 levels were significantly higher in the F4 group than in 
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healthy controls, as shown in Fig. 3 (p < 0.01). Grade 2 steatosis, grade 3 inflammation, and 
grade 2 ballooning tended to be linked to higher serum TIMP-1 levels (Table 5). Serum TIMP-
2 levels exhibited a slight trend toward being higher in the grade 3 inflammation and F4 groups 
than in healthy controls. A statistically significant correlation was observed between serum 
TIMP-1 levels and fibrosis stage (p = 0.038). 
 
Serum cytokine levels in patients with NASH 
It has been reported that HSCs, KCs, and endothelial cells are activated during NASH 
progression by cytokines via paracrine and autocrine pathways. Serum SDF-1α, SCGF-β, SCF-
1, G-CSF, MCP-1, leptin, and ghrelin levels were measured in patients with early- and 
advanced-stage NASH. 
 
Serum SDF-1α levels: Serum SDF-1α levels were significantly higher in both patients with 
early- and advanced-stage NASH than in controls (p < 0.001, Fig. 2), and its levels were higher 
in patients with advanced-stage NASH than in those with early-stage NASH (p = 0.004). 
Patients with grades 1–2 steatosis; grades 2–3 inflammation; grades 1–2 ballooning; and 
F2, F3, or F4 exhibited significantly higher SDF-1α levels than healthy controls; notably, 
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patients with F4 and clinical liver cirrhosis had the highest SDF-1α levels, as shown in Table 
6. The correlations between serum SDF-1α levels and histological grades (steatosis, 
inflammation, ballooning, and fibrosis) were all statistically significant (p = 0.005, p < 0.001, 
p = 0.002, and p < 0.001, respectively, Table 4). 
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Serum SCF-1 levels: Serum SCF-1 levels tended to be higher in the grade 1 steatosis; grades 
1 and 3 inflammation; grade 1 ballooning; and F1, F3, and F4 groups (Table 6). The grade 2 
steatosis, grades 1 and 3 inflammation, and F1, F3, and F4 groups tended to exhibit higher 
SCF-1 levels. No correlation between serum SCF-1 levels and histological grade was observed 
(Table 4). Serum SCF-1 levels did not parallel serum SDF-1α and SCGF-β levels. 
 
Serum SCGF-β levels: Serum SCGF-β levels were significantly higher in patients with 
advanced-stage NASH than in controls (p = 0.001, Fig. 2). Grade 2 steatosis, grades 2–3 
inflammation, grade 2 ballooning, and F1 and F3 tended to be associated with higher SCGF-β 
levels (Table 6). Serum SCGF-β levels did not parallel serum SDF-1α levels. Notably, serum 
SCGF-β levels were not elevated in the F4 group. The correlations of serum SCGF-β levels 
with steatosis, inflammation, and ballooning grades were significant (p = 0.025, p = 0.012, and 
p = 0.008, respectively, Table 4). Excluding the F4 group, serum SCGF-β levels were extremely 
similar to those of SDF-1α. 
 
Serum G-CSF levels: Serum G-CSF levels were significantly higher in patients with early-
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stage NASH (Fig. 2). Serum G-CSF levels were significantly higher in the grade 2 
inflammation and F3 groups than in healthy controls (Table 6). Serum G-CSF levels were also 
elevated for all-grade steatosis, grades 1 and 3 inflammation, grades 1–2 ballooning, and F1 
and F2, albeit without significance (Table 6). Among these data, it is of special interest that the 
F3 group displayed the highest G-CSF levels, whereas G-CSF levels were similar between the 
F4 and healthy control groups. No correlation between serum G-CSF levels and any 
histological finding was observed (Table 4). Serum G-CSF levels were extremely similar to 
SCF-1 and MCP-1 levels in all groups excluding the F4 group. 
 
Serum MCP-1 levels: Serum MCP-1 levels were higher in patients with early- and advanced-
stage NASH than in healthy controls (p < 0.05 and p < 0.01, respectively) (Fig. 2). Serum 
MCP-1 levels were significantly higher in the grades 2–3 steatosis, grade 2 inflammation, grade 
2 ballooning, and F1 groups than in healthy controls (Table 6). Statistically significant 
correlations were observed between serum MCP-1 levels and all histological grades, including 
those for steatosis, inflammation, ballooning, and fibrosis (p = 0.002, p = 0.005, p = 0.001, and 
p = 0.046, respectively, Table 4). Serum MCP-1 levels were similar to those of SDF-1α and 
SCGF-β. 
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Serum leptin levels: Serum leptin levels were significantly higher in both patients with early- 
and advanced-stage NASH than in healthy controls (p < 0.01 and p < 0.05, respectively), as 
shown in Fig. 2. Serum leptin levels were elevated according to the grade of steatosis and 
inflammation without statistical difference (Table 6). The grade 2 ballooning and F1 groups 
displayed statistically higher leptin levels than the healthy controls, as shown in Table 6. 
Statistically significant correlations of serum leptin levels with all histological findings, 
including steatosis, inflammation, ballooning, and fibrosis, were noted (p = 0.001, p = 0.002, 
p = 0.004 and p = 0.038, respectively, Table 4). Serum leptin levels were similar to those of 
SDF-1α, SCGF-β, and MCP-1 for all histological findings excluding fibrosis. Serum leptin 
levels appear to be related to steatosis and inflammation. 
 
Serum ghrelin levels: Serum ghrelin levels were similar between patients with NASH and 
healthy controls (Fig. 2). Serum ghrelin levels were unique for all histological findings because 
they were the reverse of those in healthy controls, albeit without statistical difference (Table 
6). An inverse but insignificant correlation was noted between serum ghrelin levels and all 
grades of histological findings (Table 4). 
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Serum MMP/TIMP and cytokine levels in relation to the clinical course of NASH 
Although we could not perform repeated liver biopsies in the same patient, disease activity 
in patients with NASH was determined using serum ALT levels. Overeating, increases in body 
weight, and low physical activity can lead to increases in serum ALT levels, and thus, we 
investigated whether serum MMP, TIMP, and cytokine levels changed in relation to changes in 
serum ALT levels in individual patients. It is necessary to further clarify whether increases in 
ALT levels accompany changes in serum cytokine levels due to changes in MMP and/or TIMP 
levels. 
 
Clinical courses of two patients: We present the clinical courses of two patients, including one 
patient with early-stage NASH and one patient with advanced-stage NASH, to better 
understand disease activity. The first case involved a 38-year-old man who developed NAFLD 
due to metabolic syndrome (BMI = 25.9, waist = 91 cm) in 2009. Liver biopsy performed in 
March 2014 revealed diffuse steatosis with large droplets in hepatocytes in the pericentral 
region and intermediate zone with small lymphocyte infiltration, suggesting grade 3 steatosis, 
grade 1 inflammation, grade 2 ballooning, and stage 1 fibrosis. We categorized this patient as 
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having early-stage NASH (Fig. 4A, No.13 in Supplementary Table 1). The patient exhibited 
hyperlipidemia and received ezetimibe, which decreased his LDL (Fig. 4A) and TG levels (data 
not shown). As his ALT levels remained elevated after 10 months of ezetimibe treatment, the 
anti-insulin resistance agent pioglitazone (15 mg/day) was prescribed. Fourteen months of 
treatment with pioglitazone and ezetimibe gradually lowered the patient’s ALT level to a 
normal value of 20 IU/l. His AST and serum γ-GTP levels also improved. Serum levels of 
MMP-1 and MMP-9 decreased gradually, as shown in Fig. 4A. 
Figure 4B shows the clinical course of a 46-year-old man with metabolic syndrome (BMI 
= 26, waist = 90 cm) who was diagnosed with advanced-stage NASH via liver biopsy in July 
2013 (Supplementary Table 1, No. 6). Histological findings revealed remarkable lymphocyte 
infiltration in the portal region, mild proliferation of bile ductules, and bridging fibrosis. The 
patient had hyperlipidemia and elevated fasting blood glucose and HbA1c levels. He also 
exhibited depression, resulting in excessive eating and lowered physical activity as well as 
altered ALT, AST, and γ-GTP levels. The changes in ALT levels were not correlated with serum 
MMP-1 levels, but lowered MMP-1 levels preceded the decline in ALT levels in this patient. 
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Fig. 4. Clinical courses of one patient with early-stage NASH and one patient with advanced-
stage NASH. 
A: Patient with early-stage NASH. 
(a) HE staining (×100). (b) Silver impregnation (×100). 
B: Patient with-stage NASH. 
(c) HE staining (×100). (d) Mallory’s AZAN staining (×100). 
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Discussion 
Leptin is a well-known cytokine that is related to obesity via its absence or insufficient 
signaling. It also reduces the development of fibrosis in models of liver injury. (113) KCs 
have been identified as the cellular targets of the profibrogenic action of leptin. (114) The 
present study revealed a significant correlation between serum leptin levels and grades of 
steatosis and inflammation (r = 0.505, p < 0.001; and r = 0.483, p < 0.002, respectively). 
Serum leptin levels were not elevated in the F4 group even though multiple intracellular 
signaling pathways in HSCs were reported to be activated by leptin. (115) However, rat 
HSCs exposed to leptin maintained a quiescent state due to the inhibitory activity of PPARγ. 
(116) This result is consistent with our present findings. 
Ghrelin is an appetite-stimulating hormone with an opposite function to leptin. Machado 
et al. reported that ghrelin is associated with more severe NAFLD. (117) Another report by 
Gonciarz et al. revealed no significant difference in ghrelin plasma levels in patients with 
NASH who were treated with melatonin. (118) Ghrelin is an important cytokine in patients 
with NASH requiring further research. 
We previously observed MMP-1 expression in MCs, KCs, and HSCs in patients with early-
stage NASH and in HPCs and HSCs in patients with advanced-stage NASH via 
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immunohistochemistry (IHC) and immunoelectron microscopy (IEM). Our study suggests that 
MMP-1 can activate KCs, HSCs, endothelial cells, and HPCs and transform these cells into 
ductular cells, myofibroblasts, and elongated repaired endothelial cells, leading to fibrosis and 
angiogenesis. (109) We then measured the serum levels of MMP-1 in patients with NASH. As 
shown in Fig. 4, changes in ALT values paralleled the serum levels of MMP-1. Our intention 
was to investigate serum MMP-1 levels in patients with NASH relative to ALT values, which 
to some extent reflect the disease activity of NASH. (6) 
The present study uncovered the mechanisms underlying the novel finding that serum 
MMP-1 levels are higher in patients with F1 NASH than in those with F2–F4 NASH and 
healthy controls. This increase in MMP-1 levels in the early stage of NASH appears to parallel 
the intensity of MMP-1 staining in MCs, KCs, and HSCs according to IHC and IEM. TG 
deposits in hepatocytes cause steatosis and inflammation in early-stage NASH. Thus, oxidative 
stress and apoptosis of hepatocytes may lead to MC and KC infiltration. (4, 5, 109) MMP-1 in 
MCs, KCs, and HSCs may be caused by cytokines, as described later in the text, and MMP-1 
expression was observed in these cells. 
Among MMPs/TIMPs and cytokines, the serum MMP-1 level best reflected disease 
activity in the clinical course of NASH. Oxidative stress in mitochondria is an essential trigger 
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of the pathogenesis of NASH, in which serum MMP-1 levels are reflected and serum MMP-9 
levels are related to the severity of steatosis and inflammation. The exact localization has not 
been observed in humans, but the cells responsible for producing MMP-9 may be 
hematopoietic stem cells and their derivative granulocytes. (119) In the present study, serum 
MMP-9 levels in patients with NASH did not parallel the disease activity. Serum MMP-2, 
TIMP-1, and TIMP-2 levels indicate the progression of fibrosis, but they did not reflect 
steatosis and inflammation in the present study. Miele et al. (120) and Toyoda et al. (121) 
reported higher serum MMP-2 and TIMP levels, but they did not examine these values in 
relation to disease activity. 
Next, we compared the serum levels of MMPs and TIMPs with those of cytokines, i.e., 
SDF-1α, SCGF-β, SCF-1, MCP-1, G-CSF, leptin, and ghrelin, in patients with NASH from the 
viewpoint of histological grading relative to the progression of NASH. Among these cytokines, 
serum of SDF-1α and SCGF-β levels were extremely similar, and those of SCF-1, MCP-1, G-
CSF, and leptin were similar. The former group also displayed levels similar to those of MMP-
2 and TIMPs, and the latter value reflected the beginning of steatosis with inflammation. Serum 
ghrelin levels differed from those of the other cytokines.  
We measured the levels of the seven aforementioned cytokines. Each cytokine has a 
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different physiological function. Marra and Tacke reported that KCs, injured hepatocytes, 
and activated HSCs secrete high levels of MCP-1, which promote the hepatic accumulation 
of bone marrow-derived CCR2-expressing MCs that massively expand the local 
macrophage pool. (122) In the present study, a significant increase in serum MCP-1 levels 
was observed in the early stage, probably subsequent to the development of steatosis in 
hepatocytes. G-CSF has been reported to prevent the development of hepatic steatosis in 
rat NASH models. (123) Moreover, acute liver failure in rats following exposure to D-
galactosamine revealed that G-CSF enhanced the SDF-1 gradient between bone marrow 
and the liver, inducing the chemoattraction of CD34+ cells from bone marrow to the injured 
liver. (124) Although this model was not a NASH model, G-CSF may increase SDF-1 levels. 
SDF-1 is the main factor regulating the trafficking and homing of hematopoietic stem cells 
to bone marrow. (16) Sinusoidal endothelial cells represent one of the main cellular sources of 
SDF-1 in the liver, and the SDF-1/CXCR4 axis is involved in the regulation of hematopoietic 
stem cell migration to the liver. (16) SDF-1α secreted by KCs activates HSCs via CXCR4 on 
the HSC membrane. (125) This SDF-1α–CXCR4 system directly activates HSCs, which 
transform into myofibroblasts and express CXCR4 on their membranes. (125) Hong et al. (18) 
reported that activation of the CXCR4 receptor of SDF-1α causes inflammation and 
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fibrogenesis in the liver. Autocrine SDF-1α expression by activated HSCs was enhanced with 
the progression of NASH because activated HSCs in the NAFLD rodent model both increased 
the number of CXCR4 and enhanced the binding affinity of SDF-1α to CXCR4. (126) The 
present study revealed that serum SDF-1α levels significantly increased with increasing 
severity of fibrosis, and a correlation between serum SDF-1α levels and fibrosis was observed 
(r = 0.649, p < 0.001). Moreover, serum SDF-1α levels significantly increased with increasing 
severity of steatosis and inflammation. 
Serum SCGF-β and SCF levels were measured in the present study because the progression 
of NASH involves the proliferation and migration of stem cells and HPCs.(109) No reports 
were found regarding the serum levels of either SCGF-β or SCF in patients with NASH. Serum 
SCGF-β and SCF levels appear to be related to inflammation. 
In summary, in patients with F1 NASH, HSCs are activated by inflammation of the liver 
due to MCP-1 and leptin, after which early liver fibrosis and collagen production occur. HSCs 
activated by inflammation promote hepatic fibrosis and secrete MMP-1. However, TIMP levels 
were not elevated in the early stage of NASH. Moreover, our previous study revealed that 
inflammation in hepatocytes promotes the recruitment and growth of HPCs arising from 
Hering’s canal and that MMP-1 is highly expressed. The expression of MMP-1 by HPCs is 
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observed strongly in early-stage NASH. Therefore, it is believed that MMP-1 contributes to 
collagen degradation in early-stage NASH, particularly in patients in the F1 group, and it may 
be involved in the pathogenesis of NASH. 
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Chapter 3 
Background 
Chapter 2 described the characteristics of MMP-1 in the early fibrosis stage of NASH. This 
section discusses the relationship between serum MMP/TIMP levels and the changes in ALT 
levels following pioglitazone treatment in patients with NASH and diabetes mellitus. 
 
Methods 
NASH is generally treated via diet modification and increasing physical activity. If 
abnormal serum TG and/or low-density lipoprotein cholesterol (LDL) levels were observed in 
individual laboratory data, lipid-lowering agents such as HMG-CoA reductase inhibitors, 
bezafibrate, and ezetimibe were prescribed. If the patients had diabetes mellitus, appropriate 
anti-diabetic drugs were prescribed according to the guidelines of the Japan Diabetes 
Association (2016). Most patients with NAFL had a good clinical course following these 
treatments. If patients with NASH did not experience improvement in this study, the anti-
insulin resistance agent pioglitazone was administered. 
In 15 of 33 patients with NASH, serum MMP/TIMP and cytokine levels were measured 0, 
21, 35, and 70 weeks after liver biopsy. ALT levels were compared with serum MMP, TIMP, 
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and SDF-1α at the same time points. 
The numbers of patients with NASH treated with pioglitazone for more than 2 months who 
underwent measurements of serum MMP, TIMP, and SDF1-α levels were as follows: six 
patients in the F1 group, nine patients in the F2 group, and one each patient in the F3 and F4 
groups. Clinical manifestations, physical findings, and clinical hematological data revealed no 
changes between before and after 2 months of pioglitazone treatment. 
 
Results 
ALT improved group vs. ALT uncontrolled group 
The ALT improved group (n = 8) exhibited ALT levels of less than 30 IU/l at 70 weeks, as 
well as decreased serum MMP-1 levels, although statistical significance was not observed (Fig. 
5). On the contrary, serum MMP-1 levels in seven patients in the ALT uncontrolled group were 
unchanged or elevated during the clinical course, as shown in Fig. 5. Moreover, serum MMP-
1 levels at 70 weeks were lower in the ALT improved group than in the ALT uncontrolled group, 
albeit without significance. This leads us to believe that serum MMP-1 levels in patients with 
NASH may represent a useful indicator of disease progression. 
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Fig. 5. Clinical courses of the ALT improved and ALT uncontrolled groups: Relationships of 
ALT changes with serum MMP/TIMP and SDF-1α levels. 
The ALT improved and uncontrolled groups included seven and eight patients, respectively. 
Each plot indicates the mean value of each group. 
 
Pharmacological effects of pioglitazone on serum ALT, MMP, TIMP, and SDF-1α levels 
ALT levels tended to decrease in the F1 and F2 groups after pioglitazone administration (p 
= 0.225 and p = 0.074, respectively). Serum MMP-1 levels in the F1 group tended to decrease 
markedly after pioglitazone treatment, whereas those in patients in the F2 group were either 
unchanged or slightly decreased (Fig. 6). Serum MMP-9 levels in the F2 group declined 
following pioglitazone administration, whereas those of MMP-2, TIMP-1, and TIMP-2 were 
not altered by treatment (Fig. 6). Serum SDF-1α levels in the F1 group increased after 
pioglitazone administration (Fig. 6), albeit without significance (p = 0.110). There was no 
change in SDF-1α levels in the F2 group. 
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Fig. 6. Effect of pioglitazone administration for 2 months on serum MMP/TIMP and SDF-1α 
levels in the F1 and F2 groups. 
Number of F1 patients, 6; number of F2 patients, 9 
 
Effects of extrahepatic inflammatory conditions on serum MMP-1 levels 
NASH is often accompanied by atherosclerosis, diabetes, and cardiovascular disease. In 
total, 15 patients with NASH underwent repeat serum MMP-1 measurements. Seven patients 
had neither diabetes nor metabolic syndrome. Five patients had both diabetes and metabolic 
syndrome, all of whom were in the ALT uncontrolled group. The remaining three patients had 
only metabolic syndrome. 
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The relationship between serum MMP-1 and HbA1c levels 
Five patients with diabetes in the ALT uncontrolled group exhibited slightly higher HbA1c 
levels of 5.8–6.6%. Serum MMP-1 levels in the ALT uncontrolled group were not correlated 
with changes in HbA1c and ALT levels. 
 
Relationship between serum MMP-1 levels and the clinical findings of metabolic syndrome 
Three patients with NASH and metabolic syndrome were included in the ALT improved 
group. In two of these patients, serum MMP-1 levels decreased with decreases in ALT levels 
and body weight. One patient displayed no changes of serum MMP-1 levels despite decreases 
in body weight. The remaining five patients with NASH and metabolic syndrome also had 
diabetes, and all of these patients were in the ALT uncontrolled group. One of these patients 
exhibited decreases in body weight and serum MMP-1 levels despite increases in ALT levels. 
Similarly, changes in waist circumference, blood pressure, and serum LDL-cholesterol and TG 
levels were not consistent with serum MMP-1 levels. 
 
Discussion 
The results revealed a decrease in MMP-1 levels in patients with improved ALT levels. 
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Lifestyle modification (diet/exercise therapy) effectively reduces ALT levels, body weight, and 
fat levels in patients with NAFLD. In this study, the completion rate for diet/exercise therapy 
was not obvious, but the success of treatment can be evaluated using ALT changes. However, 
as diet/exercise therapy and drug therapy were conducted in combination, which treatment was 
more responsible for reductions of MMP-1 levels is unclear. Furthermore, it was not possible 
to verify the effect of fibrates, statins, and ezetimibe in combination with pioglitazone, nor was 
it possible to verify whether histological improvement occurred. 
The therapeutic evaluation of NASH is important for improving steatosis, inflammation, 
and fibrosis in liver tissue. Liver biopsy could not be repeatedly performed in the same patients. 
Nakayama et al. (127) confirmed via liver biopsy that long-term treatment with pioglitazone 
for 2 years resulted in decreases in ALT levels and improvements in steatosis, inflammation, 
and fibrosis in patients with NASH. It is believed that the condition of liver tissue was improved 
also in this study. Interestingly, the MMP-1 concentration was high in the ALT improved group 
and conversely low in the ALT uncontrolled group. MMP-1 levels might predict 
responsiveness to treatment. In other words, in patients with mild fibrosis (e.g., F1), MMP-1 is 
not suppressed by TGF-β and TIMPs. In fact, in the F2 group, in which fibrosis reached the 
portal vein, serum MMP-1 levels were low. Therefore, it is believed that liver fibrosis is more 
  74 
easily improved. Although HPC and HSC activation contributed to the increased MMP-1 
concentration, some other factors may also influence treatment reactivity. 
Pioglitazone, an adipocyte PPARγ agonist, promotes TG uptake by adipocytes and 
decreases free fatty acid uptake by hepatocytes. Pioglitazone also improves insulin resistance 
through AdipoR1/R2 by increasing the blood adiponectin levels via PPARγ activation in 
muscle, adipocytes, and the liver. Via another mechanism, the drug decreases HSC activation 
by inhibiting the activity of macrophages similarly as KCs via PPARγ. As a result, pioglitazone 
decreases MCP-1 concentrations and reduces liver inflammation and fibrosis. From these 
results, the improvements of fatty liver and inflammation were believed to reduce MMP-1 
levels through reductions of collagen production. 
Metformin is mainly administered to treat diabetes, whereas pioglitazone is selected for 
patients with NASH complicated by diabetes. Of course, it is believed that metformin also 
improves NASH-induced inflammation by reversing insulin resistance and thus improving 
fatty liver. (128-130) In addition, it was recently reported that SGLT2 inhibitors are effective 
for treating NASH. (131, 132) It is thus necessary to study changes in serum MMP-1 
concentrations during treatment with these drugs. 
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Overall discussion 
NASH is often accompanied by atherosclerosis, diabetes, and cardiovascular disease. (133) 
The present study demonstrated that HbA1c levels and the clinical findings of metabolic 
syndrome, as markers of extrahepatic inflammatory conditions in NASH, were not associated 
with serum MMP-1 levels. The numbers of patients with NASH complicated by diabetes or 
metabolic syndrome were not sufficient to draw definitive conclusions. Further investigations 
with larger sample sizes are needed to clarify whether serum MMP-1 and SDF-1α levels are 
useful biomarkers of disease activity and disease progression in the F1 group of NASH, 
whether extrahepatic conditions affect serum MMP-1 levels, and whether pioglitazone 
treatment reduces MMP-1 levels in parallel with serum ALT levels. Belfort et al. (134) reported 
significant improvements of steatosis, inflammation, and hepatocyte ballooning in patients 
treated with pioglitazone due to improvements in insulin resistance. In particular, they reported 
that the rate of steatosis was significantly lower in the pioglitazone treatment group than in the 
placebo group, whereas plasma adiponectin levels were increased. When pioglitazone was 
administered for at least 2 years, Nakayama et al. (127) reported significant improvements of 
ALT, total cholesterol, and HbA1c levels and histologically observed improvements 
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droplet levels, intravesicular inflammation, and fibrosis. Pioglitazone decreased MMP-1 levels 
and increased SDF-1α levels in patients with F1 NASH. These trends were not observed in 
other fibrosis groups, suggesting that extremely complex cytokine reactions in this particular 
stage of disease lead to improvement or progression of NASH. 
This study excluded patients with findings of atherosclerosis and cardiovascular disease. 
Indeed, it is an important question whether MMP-1/TIMP-1 affects atherosclerosis and 
cardiovascular disease. Lehrke et al. reported that serum MMP-1 is associated with coronary 
artery disease (135), whereas other researchers noted that MMP-1/TIMP-1 is not correlated 
with the risk of atherosclerosis. (136) Thus, the relationships of MMPs with atherosclerosis 
and cardiovascular events are unclear. It is considered that liver weight is particularly high in 
the human body, and fibrotic livers are rich in collagens. Therefore, even if the MMP/TIMP 
concentration is elevated in patients with atherosclerosis and cardiac disease, the influences of 
these diseases on MMP levels is expected to be small. In patients with type 1 or 2 diabetes, an 
increase in MMP levels has been associated with cardiovascular events. (137-139) These 
reports describe that MMPs are associated with cardiovascular event risk in patients with type 
1 diabetes, and it is difficult to provide a similar explanation for patients with NASH but no 
cardiovascular events in the present study. Although the relationship between diabetes and 
  77 
MMPs/TIMPs should be elucidated more deeply, when focusing on collagen in the fibrotic 
liver and MMP as a collagen-degrading enzyme, serum MMP/TIMP levels appear to have a 
closer association with fibrosis in patients with NASH. 
Recently, we published a report on the spatiotemporal expression of MMP-1 in the livers 
of patients with histologically proven NASH. (109) IHC and IEM revealed that MCs, KCs, and 
HSCs were positive for MMP-1 in the early stage of NASH, whereas HPCs positive for MMP-
1 expression appeared to transform into both bile ductules participating in ductular reactions 
and elongated capillary endothelial cells involved in angiogenesis in the advanced stage of 
NASH. MMP-1–positive HPCs were observed in the early stage of NASH. (140) MMP-1, a 
soluble-type MMP, is a typical interstitial collagenase. Moreover, MMP-1 possesses both the 
unique function of degrading type I collagen at one-quarter distance from the N-terminus of 
the collagen molecule (141) and the abilities to initiate cell proliferation (79, 90, 142) and alter 
cell phenotype. (143) 
We then measured serum MMP-1 levels in patients with histologically proven NASH in 
comparison with those in healthy controls. We measured MMP-1 as well as other MMPs, 
TIMPs, SDF-1α, and several cytokines to examine disease activity linked with progression to 
advanced-stage NASH, cirrhosis, and HCC. (109) In the present study, we found that serum 
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MMP-1 levels uniquely reflect disease activity compared with those of other MMPs, their 
inhibitors, and cytokines involved in their activation and discuss the possibility of translational 
research to inhibit exosomes from KCs, MCs, and HSCs, including miRNAs related to MMP-
1 expression as novel targets for NASH. 
We additionally observed the dual expression of MMP-1 and OV-6/K19 in HPCs, ductular 
cells, and so-called small hepatocytes, suggesting that MMP-1–positive HPCs differentiated or 
transformed into hepatocytes, ductular cells, myofibroblasts, and elongated repaired 
endothelial cells, as described previously. (109) The mechanism of MMP-1 expression in MCs, 
KCs, and HSCs may involve exposure to exosomes containing miRNAs related to the 
appearance of MMP-1 secreted from MCs. (144) MMP-1 plays a central role in degrading the 
extracellular matrix in the recovery phase of experimental liver fibrosis in rats (4, 79, 90, 141, 
142, 145), but MMP-1 appears to induce cell dedifferentiation. (109) MMP-1 is considered to 
be involved in the progression of NASH pathology. (109) MMP-1 may play a kick-starter role 
as a rapid reaction to oxidative stress; i.e., higher levels of MMP-1 contribute to further 
progression to NASH. 
Immature HSCs/HPCs have been shown to exit from circulation and lodge nearby in the 
outer wall of the endothelium in experimental animals. (146) We demonstrated the expression 
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of Angiotensin II receptor-like 1 (APJ) in HSCs/HPCs related to ECs and PCs in human liver. 
(147) Hypoxia is associated with the development and progress of NAFLD and lipid 
metabolism in the liver. (148) It has been well established that hypoxia/ischemia triggers 
HSCs/HPCs to migrate from the bone marrow into peripheral blood. (149) After migration to 
the site of hypoxic/ischemic tissue, HSCs/HPCs can differentiate into ECs and participate in 
the formation of novel vessels. HIF 1α is a key determinant of oxygen dependent gene 
regulation in angiogenesis, which has been shown to be involved in HSC/HPC proliferation 
and differentiation, through low oxygen tension (hypoxia), which has been termed “hypoxic 
niche”. (149) HIF-1α, as well as its downstream apelin/APJ signaling, were upregulated in 
hypoxia-treated HPCs, and might therefore serve as a potential target for the prevention of 
hypoxic ischemic injury in vitro. (150) In sprouting angiogenesis, angiopoietin-1 and apelin 
function as important factors that support mature ECs sprouting from pre-existing vessels. 
(151) APJ was highly expressed in HSCs and hepatocytes in cirrhotic liver, suggesting that 
hypoxia and inflammatory factors could play major roles in the activation of the hepatic apelin 
system, which can lead to angiogenic and fibroproliferative responses in chronic liver disease. 
(152) HSCs/HPCs expressing APJ may contribute to the angiogenesis of liver tissue in early-
stage NASH. We expect that APJ and MMP-1 contributes to expression of HPCs and 
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regeneration of hepatocyte. Currently, relationship of APJ and MMPs have been reported in 
osteoarthropathy and rheumatoid patients(153, 154), but NASH has not reported yet. These 
relationships should be clarified in future research. 
Rapamycin (sirolimus) has been reported as an agent that inhibits the mRNA 
transcription of MMP-1. Rapamycin may exert direct antifibrotic effects independent of its 
immunosuppressive action. It efficiently activates AP-1–driven transcription by rapidly 
inducing c-Jun/AP-1 phosphorylation with activation of the c-Jun N-terminal kinase cascade, 
resulting in enhanced binding of AP-1. (155) Although what MMP-1 inhibitor will induce or 
inhibit early NASH development is unclear, it is expected that inhibitors can be applied to 
elucidate the relationship between MMP-1 and NASH. 
Autotaxin (ATX) is currently under investigation as a new-generation fibrosis maker for 
patients with chronic hepatitis C (CHC) in a parallel study. ATX is a secreted enzyme 
originally discovered in conditioned medium from A2058 human melanoma cell cultures. 
(156) ATX has an important enzymatic function in converting lysophosphatidylcholine to 
lysophosphatidic acid (LPA), which has various physiological roles in cell migration, 
neurogenesis, angiogenesis, smooth-muscle contraction, platelet aggregation, and wound 
healing. (157-160) LPA also stimulates the proliferation and contractility of HSCs. (161) 
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ATX is present in serum, and it is metabolized by liver sinusoidal endothelial cells. Fibrosis 
reduces the capacity of the liver to metabolize ATX, resulting in increases in serum ATX 
levels. (162, 163) ATX is useful as a serum marker for determining the fibrosis stage in 
patients with CHC. (164, 165) In addition, ATX is suggested to be useful as an indicator of 
the severity of liver disease and for determining the prognosis of cirrhosis (166) and HCC 
recurrence in combination with the levels of LPA receptors. (167) Liver fibrosis associated 
with CHC progression via liver inflammation, and it increases the risk of liver cirrhosis and 
(HCC). (168) When used to treat CHC, direct-acting antiviral agents (DAAs) achieve high 
sustained virological response rates. However, despite viral elimination, the risk of 
progression from liver fibrosis to cirrhosis and carcinogenesis remains. (169, 170) Therefore, 
liver fibrosis must be monitored after DAA treatment, and the optimal strategy for 
monitoring liver fibrosis is a similar problem for NASH. 
Invasive and noninvasive methods are used to monitor liver fibrosis. Invasive liver biopsies 
are difficult to undertake regularly because of the risk of bleeding, the length of hospitalization 
required to manage these risks, and the associated costs. (52) Transient elastography (TE) and 
blood sampling to determine the fibrosis marker levels are less invasive liver fibrosis 
monitoring methods. TE determines the degree of hepatic fibrosis, (171, 172); however, it 
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requires expensive equipment, the recruitment of experienced technicians, and extended 
consulting hours, and patient throughput is low. Measuring fibrosis marker concentrations in 
blood can indicate the stage of liver fibrosis, and the related costs are generally lower than 
those associated with TE. Therefore, biomarkers for early-stage NASH discovery could be 
applied to patients who cannot undergo liver biopsy and people who complete annual health 
examinations. 
In the future, fibrosis markers can be used for both diagnosis and treatment. This study 
should contribute to the early detection of NASH and evaluation of drug efficacy. In future 
research, we will examine the relationships of fibrosis markers with drugs used for the 
elucidation and treatment of MMP-1–related conditions in NASH in more detail. In addition, 
I would like to apply these strategies to clinical trials aiming to personalize medicine using 
hepatic fibrosis markers such as SDF-1α and ATX in combination. 
 
 
Conclusion 
MMP-1 is considered a biomarker for the early detection and treatment evaluation of early-
stage NASH, which is typified by increasing serum levels of leptin and MCP-1. 
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